Gender Differences in HIV Risk-Factors in Main-Partner Relationships

2011 ◽  
Author(s):  
Danielle Uding ◽  
Kanisha Collie ◽  
Kevin Wells ◽  
Zoe Peterson ◽  
Akshay Iyengar ◽  
...  
2017 ◽  
Vol 2 ◽  
pp. 100-106 ◽  
Author(s):  
Mohammad Reza Maracy ◽  
Shayan Mostafaei ◽  
Mohsen Moghoofei ◽  
Marjan Mansourian

2018 ◽  
Vol 80 (4) ◽  
pp. e13029
Author(s):  
Steven E. Bosinger ◽  
Gregory K. Tharp ◽  
Nirav B. Patel ◽  
Chunxia Zhao ◽  
Tamika L. Payne ◽  
...  

2019 ◽  
Vol 30 (6) ◽  
pp. 569-576
Author(s):  
Ester Gutiérrez-Velilla ◽  
Francisco J Quezada-Juárez ◽  
Ivonne N Pérez-Sánchez ◽  
Maria C Iglesias ◽  
Gustavo Reyes-Terán ◽  
...  

The objective of this study was to analyze risk factors for HIV-positive tests in walk-in users and in hospitalized patients in a Mexico City hospital. We undertook a cross-sectional study based on routine HIV testing and counseling service data in adults undergoing an HIV test from January 2015 to July 2017. Multivariate analysis was performed to determine risk factors for walk-in and hospitalized patients. The results showed that 2040 people tested during the period; hospitalized patients were more likely to test HIV-positive than walk-in users (18 versus 15%; p < 0.05). HIV risk factors for hospitalized patients included being men who have sex with men (MSM) (adjusted odds ratio [aOR] 7.2, 95% CI 2.0–26.5), divorced (aOR 4.4, 95% CI 1.3–14.4), having 3–5 lifetime sexual partners (aOR 2.7, 95% CI 1.0–7.4), and being in the emergency room (aOR 3.6, 95% CI 1.1–11.3), intensive care (aOR 27.2, 95% CI 3.4–217.2), or clinical pneumology wards (aOR 33.4, 95% CI 9.7–115.2). In the walk-in group, HIV risk factors included being male (aOR 2.8, 95% CI 1.3–5.9), being MSM (aOR 4.3, 95% CI 2.0–9.5), having sex while using drugs (aOR 2.3, 95% CI 1.3–4.0), being referred by a physician for testing (aOR 3.2, 95% CI 1.6–6.3), and perceiving oneself at risk (aOR 3.8, 95% CI 2.3–6.3). Differential risk factors found among hospitalized patients and walk-in testers can be helpful in designing better HIV testing strategies to increase early diagnosis and linkage to care.


2010 ◽  
Vol 24 (3) ◽  
pp. 165-173 ◽  
Author(s):  
Arlene C. Seña ◽  
Juliana P. Hammer ◽  
Kate Wilson ◽  
Abigail Zeveloff ◽  
Julia Gamble

1999 ◽  
Vol 50 (4) ◽  
pp. 556-558 ◽  
Author(s):  
Mary F. Brunette ◽  
Stanley D. Rosenberg ◽  
Lisa A. Goodman ◽  
Kim T. Mueser ◽  
Fred C. Osher ◽  
...  

2002 ◽  
Vol 13 (1) ◽  
pp. 49-65 ◽  
Author(s):  
Amy M. Kilbourne ◽  
Brooke Herndon ◽  
Ronald M. Andersen ◽  
Suzanne L. Wenzel ◽  
Lillian Gelberg

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S512-S512
Author(s):  
Michael D Virata ◽  
Merceditas Villanueva ◽  
Janet Miceli

Abstract Background SARS-CoV-2 causes a severe respiratory illness known as COVID-19. Treatment options in the early portion of the COVID-19 pandemic included the use of antiretroviral agents i.e. protease inhibitors (PIs) such as lopinavir (LPV) that had been shown to have activity against the main proteases of SARS-CoV-2 in vitro but with very limited clinical data. Prior to the use of PIs, HIV testing would be indicated to ensure that patients who were not previously diagnosed with HIV would start appropriate HIV treatment. In this unique situation, HIV testing would be utilized not based on traditional HIV risk factors. Methods We performed a retrospective search from a specific systems database of patients admitted to Yale-New Haven Health System (YNHHS) with a diagnosis of COVID-19 infection. We identified a subset of patients who were HIV tested. Most were done prior to initiating PI treatment. Demographics, comorbidity scores and specific underlying conditions were also tabulated. We performed Kruskal Wallis and Chi-Squared analysis to test for significance between HIV- and HIV+ patients. Results The total no. of patients admitted to the YNHHS with COVID-19 infection between the period from January 6, 2020 to January 6, 2021 was 5776. A cohort 964 (16.7%) patients were screened for HIV. Much of the testing occurred in the early COVID periods (Figure 1) when PIs were considered as part of the treatment algorithm. Sixty-seven (0.07%) patients tested HIV+ with 3 (0.003%) being newly diagnosed (Fig 2). Compared to HIV- patients, HIV+ were more likely to be identified as Black, with higher mean Elixhauser Comorbidity scores and significant associations with conditions such as hypertension, pulmonary disease, complicated diabetes, liver disease, renal failure and depression (Table 1). These co-morbidities have been correlated with higher risk of hospitalization for people living with HIV (PWH). Figure 2. COVID Admission and HIV Status The graph represents HIV testing results over the entire study period. Table 1. Demographics and Comorbidites Represents demographics and comorbidities of HIV- & HIV+ patients Figure 1. COVID Admissions and HIV Testing COVID admissions over time and the performance of HIV testing Conclusion This is one of the first reports on targeted HIV testing for patients not using identifiable traditional HIV risk factors who were admitted to a large healthcare system for COVID19 infections. The percentage of newly HIV diagnosed patients from this cohort was considered to be &lt; known HIV infection rates for our population. The majority of PWH were already established in care prior to their COVID19 diagnosis. Disclosures All Authors: No reported disclosures


Sign in / Sign up

Export Citation Format

Share Document